The soluble form of IL-1 receptor accessory protein enhances the ability of soluble type IIIL-1 receptor to inhibit IL-1 action

被引:150
|
作者
Smith, DE
Hanna, R
Friend, D
Moore, H
Chen, H
Farese, AM
MacVittie, TJ
Virca, GD
Sims, JE
机构
[1] Amgen Corp, Seattle, WA 98101 USA
[2] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA
关键词
D O I
10.1016/S1074-7613(02)00514-9
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Regulation of the activity of the proinflammatory cytokine IL-1 is complex, involving transcriptional and translational control, precursor processing, a receptor antagonist (IL-1ra), and a decoy receptor. Here we report that the soluble form of the IL-1 receptor accessory protein (AcP) increases the affinity of binding of human IL-1alpha and IL-1beta to the soluble human type 11 IL-1 receptor by approximately 100-fold, while leaving unaltered the low binding affinity of IL-1ra. Soluble AcP is present in normal human serum at an average concentration greater than 300 ng/ml. These findings suggest that the soluble form of IL-1 R AcP contributes to the antagonism of IL-1 action by the type 11 decoy receptor, adding another layer of complexity to the regulation of IL-1 action.
引用
收藏
页码:87 / 96
页数:10
相关论文
共 50 条
  • [21] A Truncated Form of the Soluble IL-1 Receptor Type I Which Binds IL-1ra But Not IL-1a or IL-1a
    Caffes, P.
    Anderson, L. J.
    Vigers, G. P. A.
    Brandhuber, B. J.
    Protein Engineering, 10
  • [22] A soluble form of the IL-1R accessory protein (AcP) enhances the ability of soluble type 11 IL1R (sIL1R-II) to inhibit IL-1.
    Smith, D
    Chen, HB
    Friend, D
    Virca, D
    Ketchem, R
    Moore, H
    Hanna, R
    Sims, J
    ARTHRITIS AND RHEUMATISM, 2002, 46 (09): : S386 - S386
  • [23] Soluble Type II IL-1 decoy receptor: Reversal of autocrine and paracrine effects of IL-1 in human arthritis
    Amin, AR
    Attur, MG
    Dave, MN
    Cipolletta, C
    Patel, IR
    Abramson, SB
    Kang, P
    Goldring, MB
    FASEB JOURNAL, 2001, 15 (04): : A710 - A710
  • [24] The pattern of interleukin-1 beta (IL-1 beta) and its modulating agents IL-1 receptor antagonist and IL-1 soluble receptor type II in acute meningococcal infections
    vanDeuren, M
    vanderVenJongekrijg, J
    Vannier, E
    vanDalen, R
    Pesman, G
    Bartelink, AKM
    Dinarello, CA
    vanderMeer, JWM
    BLOOD, 1997, 90 (03) : 1101 - 1108
  • [25] Activation of acid sphingomyelinase by interleukin-1 (IL-1) requires the IL-1 receptor accessory protein
    Hofmeister, R
    Wiegmann, K
    Korherr, C
    Bernardo, K
    Kronke, M
    Falk, W
    JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (44) : 27730 - 27736
  • [26] Model of interaction of the IL-1 receptor accessory protein IL-1RAcP with the IL-1β/IL-1RI complex
    Casadio, R
    Frigimelica, E
    Bossù, P
    Neumann, D
    Martin, MU
    Tagliabue, A
    Boraschi, D
    FEBS LETTERS, 2001, 499 (1-2) : 65 - 68
  • [27] IL-1 Receptor Accessory Protein-Ig/IL-1 Receptor Type II-Ig Heterodimer Inhibits IL-1 Response More Strongly than Other IL-1 Blocking Biopharmaceutical Agents
    Hanawa, Haruo
    Ota, Yoshimi
    Ding, Limin
    Chang, He
    Yoshida, Kaori
    Otaki, Keita
    Hao, Kazuhisa
    Kasahara, Sou
    Kodama, Makoto
    Nakazawa, Mikio
    Aizawa, Yoshifusa
    JOURNAL OF CLINICAL IMMUNOLOGY, 2011, 31 (03) : 455 - 464
  • [28] IL-1 Receptor Accessory Protein-Ig/IL-1 Receptor Type II-Ig Heterodimer Inhibits IL-1 Response More Strongly than Other IL-1 Blocking Biopharmaceutical Agents
    Haruo Hanawa
    Yoshimi Ota
    Limin Ding
    He Chang
    Kaori Yoshida
    Keita Otaki
    Kazuhisa Hao
    Sou Kasahara
    Makoto Kodama
    Mikio Nakazawa
    Yoshifusa Aizawa
    Journal of Clinical Immunology, 2011, 31 : 455 - 464
  • [29] Type I IL-1 receptor mediates IL-1 and intracellular IL-1 receptor antagonist effects in skin inflammation
    Palmer, Gaby
    Talabot-Ayer, Dominique
    Kaya, Guerkan
    Gabay, Cem
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (08) : 1938 - 1946
  • [30] Inhibitory activity of IL-1 receptor antagonist depends on the balance between binding capacity for IL-1 receptor type 1 and IL-1 receptor type II
    Ruggiero, P
    Bossu, P
    Macchia, G
    DelGrosso, E
    Sabbatini, V
    Bertini, R
    Colagrande, A
    Bizzarri, C
    Maurizi, G
    DiCioccio, V
    DAndrea, G
    DiGiulio, A
    Frigerio, F
    Grifantini, R
    Grandi, G
    Tagliabue, A
    Boraschi, D
    JOURNAL OF IMMUNOLOGY, 1997, 158 (08): : 3881 - 3887